Compare CCNEP & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCNEP | SCLXW |
|---|---|---|
| Founded | 1865 | N/A |
| Country | | United States |
| Employees | 950 | 34 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | CCNEP | SCLXW |
|---|---|---|
| Price | $24.94 | $0.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.1K | ★ 2.6K |
| Earning Date | 04-17-2025 | 03-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.39 | N/A |
| Revenue | ★ $217,361,000.00 | $55,152,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.44 | ★ N/A |
| Revenue Growth | N/A | ★ 22.02 |
| 52 Week Low | $23.57 | $0.05 |
| 52 Week High | $25.44 | $0.64 |
| Indicator | CCNEP | SCLXW |
|---|---|---|
| Relative Strength Index (RSI) | 55.35 | 44.44 |
| Support Level | $24.88 | $0.11 |
| Resistance Level | $24.98 | $0.18 |
| Average True Range (ATR) | 0.11 | 0.02 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 96.07 | 53.37 |
CNB Financial Corp is a Pennsylvania-chartered bank. The bank is a full-service bank engaging in a full range of banking activities and services for individual, business, governmental and institutional customers. These activities and services principally include checking, savings, and time deposit accounts; real estate, commercial, industrial, residential and consumer loans; and a variety of other specialized financial services. Its Private Client Solutions division offers a full range of client services, including private banking and wealth and asset management. The banking segment derives its revenue through the operations as a full-service bank services, including trust and wealth management services, for individual, business, governmental, and institutional customers.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.